Ewa Nowacka-Cieciura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ewa Nowacka-Cieciura has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Magdalena Durlik
Dept of Transplantation Medicine, Nephrologu and Internal Medicine, Medical Univeristy of Warsaw, Warsaw, Poland
4 shared publicationsAnna Sadowska
Dept of Transplantation Medicine, Nephrologu and Internal Medicine, Medical Univeristy of Warsaw, Warsaw, Poland
2 shared publicationsBartłomiej Matłosz
2 shared publicationsJoanna Pazik
Dept of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
2 shared publications- Magdalena Durlik
Warsaw Medical University, Warsaw, Poland
2 shared publications Mieczysław Lao
2 shared publications
Latest Publications
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i598-i599
SP742MALNUTRITION RISK IN KIDNEY ALLOGRAFT RECIPIENTS TREATED WITH MYCOPHENOLATE MOFETIL IS ASSOCIATED WITH IMPDH1 rs2278294 POLYMORPHISM
INTRODUCTION AND AIMS: Malnutrition is known to increase morbidity and limit allograft survival in kidney recipients. Inosine monophosphate dehydrogenase (IMPDH) regulates intracellular fat accumulation and preadipicytes maturing, fat tissue is the main site of constitutive IMPDH expression. IMPDH is also a target of mycophenolic acid (MPA) used as a part of maintenance immunosuppression in acute rejection prophylactic. We have previously shown that in MPA-treated kidney transplant recipients, IMPDH1 rs2278294 polymorphism interferes with BMI gain within two post transplant years. Now we aimed to evaluate for this effect durability in the five years follow up.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i598-i599
SP742MALNUTRITION RISK IN KIDNEY ALLOGRAFT RECIPIENTS TREATED WITH MYCOPHENOLATE MOFETIL IS ASSOCIATED WITH IMPDH1 rs2278294 POLYMORPHISM
INTRODUCTION AND AIMS: Malnutrition is known to increase morbidity and limit allograft survival in kidney recipients. Inosine monophosphate dehydrogenase (IMPDH) regulates intracellular fat accumulation and preadipicytes maturing, fat tissue is the main site of constitutive IMPDH expression. IMPDH is also a target of mycophenolic acid (MPA) used as a part of maintenance immunosuppression in acute rejection prophylactic. We have previously shown that in MPA-treated kidney transplant recipients, IMPDH1 rs2278294 polymorphism interferes with BMI gain within two post transplant years. Now we aimed to evaluate for this effect durability in the five years follow up.
- 1 June 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (5) , 1561-1565
Association of MYH9 rs3752462 and rs5756168 Polymorphisms With Transplanted Kidney Artery Stenosis
- 1 June 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (5) , 1561-1565
Association of MYH9 rs3752462 and rs5756168 Polymorphisms With Transplanted Kidney Artery Stenosis
- 1 January 2006
- Published by Elsevier in Transplantation Proceedings
- Vol. 38 (1) , 165-167
Bisphosphonates Are Effective Prophylactic of Early Bone Loss After Renal Transplantation
- 1 January 2006
- Published by Elsevier in Transplantation Proceedings
- Vol. 38 (1) , 165-167
Bisphosphonates Are Effective Prophylactic of Early Bone Loss After Renal Transplantation
- 1 January 2005
- p. 46-50
[Cardiovascular risk factors and their modification after renal transplantation].
Cardiovascular disease is the leading cause of death in renal transplant recipients. Death with a functioning graft is the main cause of graft failure. Risk factors for cardiovascular complications and modification of methods are discussed.
- 1 January 2005
- p. 46-50
[Cardiovascular risk factors and their modification after renal transplantation].
Cardiovascular disease is the leading cause of death in renal transplant recipients. Death with a functioning graft is the main cause of graft failure. Risk factors for cardiovascular complications and modification of methods are discussed.
- 1 October 2003
- Vol. 15 (88) , 356
[Cytokines and growth factors serum level and renal allograft function (preliminary report)].
Long-term cyclosporine nephrotoxicity, subclinical rejections are risk factors of chronic allograft nephropathy. In a prospective, randomized study 44 pts. were randomized either to a reduced dose of CyA and daclizumab (group A, n = 22) or to a normal dose of CyA without daclizumab (group B, n = 22). Both groups were treated with MMF and prednisone. Number of rejection episodes was the primary endpoint. The secondary endpoints were renal function; histological parameters related to CyA; serum level of TGF-beta, PDGF-BB, blockade of CD25 molecule and surface expression of CD3, CD4, CD8, CD69, CD11a, CD49d, CD28, CD152 molecules in the subpopulations of T cells in the peripheral blood. A low incidence of clinically suspected rejection episodes were observed (19% in group A and 12.4% in group B; NS). The protocol biopsies at 3 month emerged 7 subclinical rejection episodes (4 in group A and 3 in group B). Serum creatinine level did not differ between examined groups. Chronic histopathologic changes related to CyA progressed significantly at the 3 month biopsies in both groups (with no differences between groups). Serum TGF-beta, PDGF did not differ between groups. Expression of CD25, CD152 molecule was significantly lower in group A than in group B. Immunosuppression regiment with low CyA dose with daclizumab, MMF, prednisone seems to be efficient and safe in low-risk rejection kidney allograft recipients.
- 1 October 2003
- Vol. 15 (88) , 356
[Cytokines and growth factors serum level and renal allograft function (preliminary report)].
Long-term cyclosporine nephrotoxicity, subclinical rejections are risk factors of chronic allograft nephropathy. In a prospective, randomized study 44 pts. were randomized either to a reduced dose of CyA and daclizumab (group A, n = 22) or to a normal dose of CyA without daclizumab (group B, n = 22). Both groups were treated with MMF and prednisone. Number of rejection episodes was the primary endpoint. The secondary endpoints were renal function; histological parameters related to CyA; serum level of TGF-beta, PDGF-BB, blockade of CD25 molecule and surface expression of CD3, CD4, CD8, CD69, CD11a, CD49d, CD28, CD152 molecules in the subpopulations of T cells in the peripheral blood. A low incidence of clinically suspected rejection episodes were observed (19% in group A and 12.4% in group B; NS). The protocol biopsies at 3 month emerged 7 subclinical rejection episodes (4 in group A and 3 in group B). Serum creatinine level did not differ between examined groups. Chronic histopathologic changes related to CyA progressed significantly at the 3 month biopsies in both groups (with no differences between groups). Serum TGF-beta, PDGF did not differ between groups. Expression of CD25, CD152 molecule was significantly lower in group A than in group B. Immunosuppression regiment with low CyA dose with daclizumab, MMF, prednisone seems to be efficient and safe in low-risk rejection kidney allograft recipients.
- 1 October 2003
- Vol. 15 (88) , 360
[The usefulness of tubular and glomerular proteinuria measurement in non-invasive diagnosis of vascular changes accompanying chronic allograft nephropathy].
Chronic allograft nephropathy (CAN) is the most important cause of late renal allograft loss. The standard diagnosis of CAN is based on pathological examinations according to Banff'97 scheme. The aim of the study was to evaluate the usefulness of tubular and glomerular proteinuria in non-invasive recognition of vascular changes accompanying CAN (AH--arteriolar hyaline thickening, CV--vascular fibrous intimal thickening). beta 2- and alpha 2-microglobulin (beta 2-m and alpha 2-m), albumin (alb), immunoglobulin G (IgG), total protein (tp) and creatinine (cr) concentration were measured in the second time urine specimen in 66 renal allograft recipients. Then the subsequent renal biopsies were done. The aim of statistical analysis (MANOVA, Stepwise Discriminant Analysis, SDA) was to diagnose CV and AH changes based on results of urine analysis listed above and the patient's age, time after transplantation and serum creatinine level (scr). Results obtained with statistical analysis were in 90.91% and 87.69% identical with CV and AH pathological diagnoses, respectively.
- 1 October 2003
- Vol. 15 (88) , 360
[The usefulness of tubular and glomerular proteinuria measurement in non-invasive diagnosis of vascular changes accompanying chronic allograft nephropathy].
Chronic allograft nephropathy (CAN) is the most important cause of late renal allograft loss. The standard diagnosis of CAN is based on pathological examinations according to Banff'97 scheme. The aim of the study was to evaluate the usefulness of tubular and glomerular proteinuria in non-invasive recognition of vascular changes accompanying CAN (AH--arteriolar hyaline thickening, CV--vascular fibrous intimal thickening). beta 2- and alpha 2-microglobulin (beta 2-m and alpha 2-m), albumin (alb), immunoglobulin G (IgG), total protein (tp) and creatinine (cr) concentration were measured in the second time urine specimen in 66 renal allograft recipients. Then the subsequent renal biopsies were done. The aim of statistical analysis (MANOVA, Stepwise Discriminant Analysis, SDA) was to diagnose CV and AH changes based on results of urine analysis listed above and the patient's age, time after transplantation and serum creatinine level (scr). Results obtained with statistical analysis were in 90.91% and 87.69% identical with CV and AH pathological diagnoses, respectively.